Favipiravir
-
SC seeks Centre's reply on plea alleging no approval for Remdesivir, Favipiravir to treat COVID-19
India | Oct 29, 2020, 01:51 PM ISTThe Supreme Court Thursday sought response from the Centre on a plea alleging that two medicines Remdesivir and Favipiravir, are being used for treatment of COVID-19 without approval.
-
Favipiravir shows promise in reining in Covid-19
Science | Oct 11, 2020, 04:07 PM ISTThe flu drug favipiravir has shown promise in preventing the coronavirus infection in rodents when administered in high doses, says a study.
-
Hetero launches pack of generic coronavirus drug favipiravir at Rs 2,640
Business | Sep 25, 2020, 06:57 PM ISTFavivir 800/200 will be available in a pack containing 16 tablets of favipiravir 800 mg and 2 tablets of favipiravir 200 mg priced at Rs 2,640 per pack, Hetero said in a statement.
-
Favipiravir tablet, Remdesivir now available in Odisha market for COVID patient's treatment
India | Sep 12, 2020, 10:06 PM ISTAmid surge of coronavirus cases in Odisha, the state government has allowed the sale of Favipiravir tablet and Remdesivir injectable formulation in stores for the treatment of coronavirus patients on Saturday.
-
FDC launches 2 variants of Favipiravir in India at Rs 55 per tablet
Business | Aug 25, 2020, 06:36 PM ISTDrug firm FDC Ltd on Tuesday said it has launched two variants of the COVID-19 drug Favipiravir under the brand names PiFLU and Favenza.
-
Zenara Pharma receives DCGI approval to manufacture, sell Favipiravir tablets
Business | Aug 05, 2020, 04:32 PM ISTThe tablet, which will be sold under the brand name 'Favizen', is being manufactured at Zenar's US FDA approved facility in Hyderabad, a press release from the drug maker said.
-
Sun Pharma launches Favipiravir in India at Rs 35 per tablet
Business | Aug 04, 2020, 04:02 PM ISTFavipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease, it added.
-
Hetero launches generic COVID-19 drug at Rs 59 per table
Business | Jul 29, 2020, 01:00 PM ISTFavivir improves treatment accessibility to a significant amount of COVID-19 patient population, which usually sustains mild to moderate symptoms.
-
Hyderabad's Avra Labs to make Favipiravir for Cipla's Ciplenza
Business | Jul 27, 2020, 03:06 PM ISTHyderabad-based Avra Laboratories Pvt Ltd announced on Monday that it had received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market Favipiravir Active Pharmaceutical Ingredient (API) for treatment of COVID-19.
-
Jenburkt Pharma launches COVID-19 drug at Rs 39 per tablet
Business | Jul 24, 2020, 07:26 PM ISTThe company hopes that the easy accessibility and affordable price point of an effective treatment such as Favivent will offer Indian citizens a timely, much-needed therapeutic solution.
-
Cipla gets nod to launch affordable Favipiravir in India for treatment of COVID-19 patients
India | Jul 24, 2020, 05:54 PM ISTPharmaceutical firm Cipla is set to launch COVID-19 drug Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process. Cipla has scaled up the process in their manufacturing facility and approached DCGI (Drug Controller General of India) for permission to launch the product in India.
-
Glenmark’s Favipiravir drug shows encouraging results in Phase 3 clinical trial
Business | Jul 23, 2020, 11:39 AM ISTGlenmark Pharmaceuticals on Thursday announced top-line results from a Phase 3 clinical trial in mild to moderate COVID-19 patients, conducted across seven clinical sites in India.
-
Glenmark releases phase-3 trial data of Favipiravir, says 40% faster 'clinical cure' witnessed
Fyi | Jul 22, 2020, 10:47 PM ISTAccording to Glenmark, 40 per cent faster achievement of "clinical cure" was witnessed in the third phase of the clinical trials of Favipiravir involving 150 patients with mild to moderate COVID-19 across seven clinical sites in India.
-
COVID-19 Drug: Biophore Pharma ramps up production of made-in-India Favipiravir, claims validation
Business | Jul 14, 2020, 01:12 PM ISTBiophore has received the DCGI license to manufacture the API in India and has been cleared for export as well. It has also received approval in Turkey in collaboration with a local Turkish partner.
-
FabiFlu: Glenmark Pharma cuts price of COVID-19 drug Favipiravir. Here's how much it will cost now
Business | Jul 13, 2020, 01:48 PM ISTGlenmark Pharmaceuticals had launched FabiFlu last month at a price of Rs 103 per tablet. In a regulatory filing Glenmark announced a price reduction of 27 per cent for FabiFlu. The new maximum retail price (MRP) is Rs 75 per tab, it said.
-
Remdesiver, Favipiravir antiviral drugs 'no game changers' in COVID-19 fight, say medical experts
India | Jun 22, 2020, 11:06 PM ISTWith pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".
-
Glenmark launches COVID-19 drug after DCGI nod
Business | Jun 20, 2020, 09:02 PM ISTGlenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.
-
DCGI approves clinical trials of Favipiravir used in influenza in Japan, China for COVID-19: CISR DG
News | May 08, 2020, 08:23 PM ISTThe Certified Insurance Service Representative (CISR) Director General Dr. Shekhar C. Mande while talking about drugs that can be useful against COVID-19 informed that the Drug Controller General of India has given approval for clinical trials of Favipiravir which is used in influenza in Japan, China etc.
-
Nigeria to get Japanese drug for Ebola treatment
World | Sep 02, 2014, 10:38 AM ISTAbuja: Nigeria will soon get a Japanese drug to treat Ebola, the country's Health Minister Onyebuchi Chukwu said on Monday.The drug named Favipiravir and developed by a subsidiary of Fujifilm Holdings in Japan, could be
-
Japan ready to offer flu drug for Ebola treatment
World | Aug 25, 2014, 05:28 PM ISTTokyo: Japan said Monday it is ready to provide a Japanese-developed anti-influenza drug as a possible treatment for the rapidly expanding Ebola outbreak.Chief Cabinet Secretary Yoshihide Suga told reporters that Japan can offer favipiravir, developed